STAT+: Halfway into the year, biotech is booming

STAT PlusOpinionAdam’s Biotech Scorecard Halfway into the year, biotech is booming Plus: What to expect at the FDA’s Capricor advisory panel meeting Manage alerts for this article Email this article Share this article By Adam FeuersteinJuly 2, 2026 Senior Writer, Biotech Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. We’ve reached the midpoint of the year and, wow, biotech has gone nuts. The sector’s performance in June was especially bonkers.Advertisement The XBI, biotech’s most-watched stock index, gained 19% over the past month and is up 30% for the year. At 158, the XBI is trading at a five-year high and approaching its peak of $175 set in February 2021. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, FDA, Pharmaceuticals, rare diseases, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Adam's Biotech Scorecard June 18, 2026 STAT Plus: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept Adam's Biotech Scorecard June 11, 2026 STAT Plus: ‘Synthetic lethality’ could trigger another round of biotech M&A Advertisement Adam's Biotech Scorecard June 4, 2026 STAT Plus: Does Revolution Medicines’ pancreatic cancer drug have even greater potential? Adam's Biotech Scorecard May 28, 2026 STAT Plus: An ASCO preview: What to watch for at cancer research’s big meeting Adam's Biotech Scorecard May 14, 2026 STAT Plus: ‘No drama’ Diamantas should serve biotech well as acting FDA chief Subscriber Picks